VES Vaccine Surveillance 2011 - 2015
Malawi, 2011 - 2015
Get MicrodataIdentification
MWI-MEIRU-VES-2011-v1
VES Vaccine Surveillance 2011 - 2015
English
| Name | Country code |
|---|---|
| Malawi | MWI |
Demographic Surveillance
The primary purpose of this study was to determine the impact of pneumococcal conjugate vaccine (PCV) on invasive pneumococcal disease (IPD) following this vaccine's introduction into the national immunization program in Malawi. Additionally, the study aimed to document changes in circulating invasive pneumococcal serotypes andstrengthen support for the continued procurement of vaccine locally. Furthermore, this evaluation aimed to provide important information for other African countries considering a similar vaccine introduction strategy. The work consisted of three parts:
- Active surveillance for invasive pneumococcal disease
- Case-control studies of vaccine-effectiveness
- Adverse events surveillance
Active, sentinel pre- and post-vaccine surveillance for IPD and serotypes was used for this study to assess the impact of vaccination on hospitalised IPD and on distribution of invasive pneumococcal serotypes. All children with clinical or radiological pneumonia who presented to Chilumba Rural Hospital (CRH) in Karonga District and who met the standard case definition were eligible for recruitment. All attendances at the facility and the proportion due to IPD and pneumonia were recorded.
To assess vaccine effectiveness a case-control design was used. Case-patients were children age-eligible to receive the vaccine and were identified by active, laboratory surveillance. Controls will be children living in the same neighbourhood of case-patients. Information on vaccination status, schedules and variables potentially affecting vaccine performance (e.g. anthropometry, sociodemographic indicators) were collected and a request for an HIV test made or consent sought to use existing HIV-infection status data. Interpreting vaccine effectiveness data in conjunction with vaccination coverage rates was also to provide indirect estimates of vaccine impact on pneumococcal burden in Malawi.
This study was also carried out at Queen Elizabeth Central Hospital in Blantyre (data not available on this catalogue).
NHSRC approval number: 837
NHSRC approval number part 2: 867
NHSRC approval number for sub study: 1073
Observational episodes
Individual
Version
2011
Scope
Vaccine surveillance, Vital signs, Vaccine history, Presenting History, Past medical history, Examination, Diagnosis, Investigations
| Topic | Vocabulary |
|---|---|
| Pneumococcal Infections | MeSH |
| Pneumococcal Conjugate Vaccine | MeSH |
| Malawi | MeSH |
| Matched Case-Control Studies | MeSH |
Coverage
Children <5 years of age in the DSS area.
Producers and sponsors
| Name | Affiliation |
|---|---|
| Nigel A Cunliffe | University of Liverpool |
| Robert S Heyderman | Liverpool School of Tropical Medicine |
| Neil French | London School of Hygiene & Tropical Medicine |
| Name | Affiliation | Role |
|---|---|---|
| Anthony Costello | University College London | Co-investigator |
| Charles Mwansambo | Ministry of Health, Malawi | Co-investigator |
| Mrs Agnes Katsulukuta | Expanded Program for Immunisations | Co-investigator |
| Andrew Gonani | Ministry of Health & Population | Co-investigator |
| Jacqueline Tate | Centers for Disease Control & Prevention, Atlanta, USA | Co-investigator |
| Umesh Parashar | Centers for Disease Control & Prevention, Atlanta, USA | Co-investigator |
| Cynthia Whitney | Centers for Disease Control & Prevention, Atlanta, USA | Co-investigator |
| Osamu Nakagomi | Nagasaki University, Japan | Co-investigator |
| Name | Abbreviation |
|---|---|
| Wellcome Trust, UK | (WT) |
| Name |
|---|
| MEIRU Core datamanagement team |
Data collection
| Start | End |
|---|---|
| 2011-08-28 | 2015-11-30 |
- Face-to-face [f2f]
| Name | Abbreviation |
|---|---|
| Malawi Epidemiology and Intervention Research Unit | MEIRU |
Access policy
Chilumba
Data Access
| Name |
|---|
| Malawi Epidemiology and Intervention Research Unit |
These data are made available for licensed access under the following conditions:
-
Data and other material provided by MEIRU will not be redistributed or sold to other individuals, institutions or organisations without MEIRU's written agreement.
-
In the case of multi-centre datasets, data originating from a single contributing member centre of the collaboration may not be analysed or reported on in isolation without the express permission of the member centre concerned.
-
No attempt will be made to re-identify respondents, and there will be no use of the identity of any person or establishment discovered inadvertently. Any such discovery will be reported immediately to MEIRU.
-
No attempt will be made to produce links between datasets provided by MEIRU or between MEIRU data and other datasets that could identify individuals.
-
Any books, articles, conference papers, theses, dissertations, reports or other publications employing data obtained from MEIRU will cite the source, in line with the citation requirement provided with the dataset.
-
An electronic copy of all publications based on the requested data will be sent to MEIRU.
Metadata production
DDI-MWI-MEIRU-Vaccine surveillance (VESE)-2011-v1
| Name | Abbreviation | Affiliation | Role |
|---|---|---|---|
| Chifundo Kanjala | CK | MEIRU | Data Documentation Project Management |
| Elizabeth Munthali | EM | MEIRU | Metadata Supervisor |
| Estelle McLean | EM | LSHTM | Production of the documentation used to create this DDI document |
2020-05-07
Metadata version
Version 1 (May 2020)